34089
document
Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas . The recurrence of hepatocellular carcinoma ( HCC ) after minimally invasive therapy is frequent . Adoptive immunotherapy is thought to be an effective method to lower recurrence and metastasis rates of malignant tumors . Therefore , 85 HCC patients after transcatheter arterial chemoembolization and radiofrequency ablation therapy were randomized to immunotherapy group and no adjuvant therapy group . Autologous cytokine-induced killer ( CIK ) cells were transfused via hepatic artery to the patients . The alteration of levels of lymphocyte subsets in peripheral blood of patients was examined by flow cytometry . All patients were screened by computed tomography every 2 months to observe the tumor recurrent conditions . After CIK cell infusions , the percentages of CD3+ , CD4+ , CD56+ , CD3+CD56+ cells , and CD4+/CD8+ ratio increased from 68.6+/-11.0 % , 31.1+/-9.0 % , 15.6+/-7.9 % , 5.2+/-3.1 % , and 1.1+/-0.5 to 70.7+/-10.1 % , 33.5+/-8.0 % , 18.4+/-9.4 % , 5.9+/-2.8 % , and 1.3+/-0.7 , respectively ( P < 0.05 ) ; whereas the percentage of CD8 cells decreased from 31.1+/-7.8 % to 28.6+/-8.3 % ( P < 0.05 ) . The 1-year and 18-month recurrence rates of the study group were 8.9 % and 15.6 % , compared with 30.0 % and 40.0 % of the control group ( both P value < 0.05 ) . The data suggest that CIK cell transfusion is an effective treatment . It can boost the immunologic function in HCC patients and plays an important role in reducing the recurrence rate of HCC .
34090
Intervention_Pharmacological
cytokine-induced killer cells
34091
Intervention_Pharmacological
Adoptive immunotherapy
34092
Intervention_Pharmacological
transcatheter arterial chemoembolization
34093
Intervention_Physical
radiofrequency ablation therapy
34094
Intervention_Pharmacological
immunotherapy
34095
Intervention_Control
no adjuvant therapy
34096
Intervention_Pharmacological
Autologous cytokine-induced killer ( CIK ) cells
34097
Intervention_Pharmacological
CIK cell
34098
Intervention_Pharmacological
CIK cell transfusion
34099
Outcome_Physical
percentages of CD3+ , CD4+ , CD56+ , CD3+CD56+ cells , and CD4+/CD8+ ratio
34100
Outcome_Physical
percentage of CD8 cells
34101
Outcome_Physical
1-year and 18-month recurrence rates of the study group
34102
Participant_Condition
hepatocellular carcinomas
34103
Participant_Sample-size
85
34104
Participant_Condition
tumor recurrent conditions
34105
Participant_Condition
HCC